New dengue vaccine trial shows promise for india
NCT ID NCT06060067
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tested Takeda's dengue vaccine (TDV) in 480 healthy people aged 4 to 60 in India. Participants received two doses of either the vaccine or a placebo, three months apart. The main goals were to check for side effects and measure the body's immune response against all four types of dengue virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Takeda's dengue vaccine (TDV, also called TAK-003)
What this could lead to
If successful, this vaccine could help protect people in India from dengue fever, a serious mosquito-borne disease.
What could go wrong
This is a Phase 3 trial focused on safety and immune response, not yet proven to prevent dengue in the real world. Side effects like injection site pain or fever are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BGS Global Institute of Medical Sciences (BGS-GIMS) #67, BGS Health & Education City, Uttarahalli Main Road, Kengeri
Bangalore, Karnataka, 560060, India
-
Chettinad Academy of Research and Education, Chettinad Health City, SH,49A, Dist. Kelambakkam
Pudupākkam, Tamil Nadu, 603 103, India
-
IPGME&R and SSKM Hospital, 244 AJC Bose Road
Kolkata, 700020, India
-
KEM Hospital Research Centre, Sandar Moodliar Road, Rasta Peth
Pune, 411011, India
-
King George Hospital
Visakhapatnam, 530002, India
-
King George's Medical University, Department of Medicine, Chowk
Lucknow, 226003, India
-
Maulana Azad Medical College & Associated Lok Nayak, Govind Ballabh Pant Hospitals and Guru Nanak Eye Center
New Delhi, 110002, India
-
Preventive and Therapeutic Clinical Trial Unit (PTCTU), Dept. of Community Medicine, Institute of Medical Science and SUM Hospital, K-8, Kalinga Nagar
Bhubaneswar, 751003, India
-
SRM Medical College Hospital & Research Centre, SRM Nagar, Potheri
Kattankulathur, 603203, India
-
Suyog Hospital, 2nd Floor, B-Wing, Krushi Utpanna Bazar, Samiti Sankul, Dindori Rd, Panchavati
Nashik, 422003, India